Safety
-
Vidaza (azacitidine) for Injection
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – January 2012
ADVERSE REACTIONS
Postmarketing Experience
- tumor lysis syndrome, injection site necrosis,and Sweet’s syndrome (acute febrile neutrophilic dermatosis) ....added
-
-







